A Quality Risk Management Model Approach for Cell Therapy Manufacturing

Fabio Lopez, Chiara Di Bartolo, Tommaso Piazza, Antonino Passannanti, Jörg C. Gerlach, Bruno Gridelli, Fabio Triolo

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

International regulatory authorities view risk management as an essential production need for the development of innovative, somatic cell-based therapies in regenerative medicine. The available risk management guidelines, however, provide little guidance on specific risk analysis approaches and procedures applicable in clinical cell therapy manufacturing. This raises a number of problems. Cell manufacturing is a poorly automated process, prone to operator-introduced variations, and affected by heterogeneity of the processed organs/tissues and lot-dependent variability of reagent (e.g., collagenase) efficiency. In this study, the principal challenges faced in a cell-based product manufacturing context (i.e., high dependence on human intervention and absence of reference standards for acceptable risk levels) are identified and addressed, and a risk management model approach applicable to manufacturing of cells for clinical use is described for the first time. The use of the heuristic and pseudo-quantitative failure mode and effect analysis/failure mode and critical effect analysis risk analysis technique associated with direct estimation of severity, occurrence, and detection is, in this specific context, as effective as, but more efficient than, the analytic hierarchy process. Moreover, a severity/occurrence matrix and Pareto analysis can be successfully adopted to identify priority failure modes on which to act to mitigate risks. The application of this approach to clinical cell therapy manufacturing in regenerative medicine is also discussed.

Original languageEnglish
Pages (from-to)1857-1871
Number of pages15
JournalRisk Analysis
Volume30
Issue number12
DOIs
Publication statusPublished - Dec 2010

Fingerprint

Risk Management
Quality management
Cell- and Tissue-Based Therapy
Risk management
Failure modes
Regenerative Medicine
Risk analysis
Cellular manufacturing
Analytic hierarchy process
Collagenases
Guidelines
Tissue
Efficiency
Healthcare Failure Mode and Effect Analysis

Keywords

  • Cell therapy
  • FMEA/FMECA
  • Pareto analysis
  • Quality risk management
  • Regenerative medicine

ASJC Scopus subject areas

  • Physiology (medical)
  • Safety, Risk, Reliability and Quality

Cite this

Lopez, F., Bartolo, C. D., Piazza, T., Passannanti, A., Gerlach, J. C., Gridelli, B., & Triolo, F. (2010). A Quality Risk Management Model Approach for Cell Therapy Manufacturing. Risk Analysis, 30(12), 1857-1871. https://doi.org/10.1111/j.1539-6924.2010.01465.x

A Quality Risk Management Model Approach for Cell Therapy Manufacturing. / Lopez, Fabio; Bartolo, Chiara Di; Piazza, Tommaso; Passannanti, Antonino; Gerlach, Jörg C.; Gridelli, Bruno; Triolo, Fabio.

In: Risk Analysis, Vol. 30, No. 12, 12.2010, p. 1857-1871.

Research output: Contribution to journalArticle

Lopez, F, Bartolo, CD, Piazza, T, Passannanti, A, Gerlach, JC, Gridelli, B & Triolo, F 2010, 'A Quality Risk Management Model Approach for Cell Therapy Manufacturing', Risk Analysis, vol. 30, no. 12, pp. 1857-1871. https://doi.org/10.1111/j.1539-6924.2010.01465.x
Lopez F, Bartolo CD, Piazza T, Passannanti A, Gerlach JC, Gridelli B et al. A Quality Risk Management Model Approach for Cell Therapy Manufacturing. Risk Analysis. 2010 Dec;30(12):1857-1871. https://doi.org/10.1111/j.1539-6924.2010.01465.x
Lopez, Fabio ; Bartolo, Chiara Di ; Piazza, Tommaso ; Passannanti, Antonino ; Gerlach, Jörg C. ; Gridelli, Bruno ; Triolo, Fabio. / A Quality Risk Management Model Approach for Cell Therapy Manufacturing. In: Risk Analysis. 2010 ; Vol. 30, No. 12. pp. 1857-1871.
@article{52de818a04d24fc299804f8dd57caccc,
title = "A Quality Risk Management Model Approach for Cell Therapy Manufacturing",
abstract = "International regulatory authorities view risk management as an essential production need for the development of innovative, somatic cell-based therapies in regenerative medicine. The available risk management guidelines, however, provide little guidance on specific risk analysis approaches and procedures applicable in clinical cell therapy manufacturing. This raises a number of problems. Cell manufacturing is a poorly automated process, prone to operator-introduced variations, and affected by heterogeneity of the processed organs/tissues and lot-dependent variability of reagent (e.g., collagenase) efficiency. In this study, the principal challenges faced in a cell-based product manufacturing context (i.e., high dependence on human intervention and absence of reference standards for acceptable risk levels) are identified and addressed, and a risk management model approach applicable to manufacturing of cells for clinical use is described for the first time. The use of the heuristic and pseudo-quantitative failure mode and effect analysis/failure mode and critical effect analysis risk analysis technique associated with direct estimation of severity, occurrence, and detection is, in this specific context, as effective as, but more efficient than, the analytic hierarchy process. Moreover, a severity/occurrence matrix and Pareto analysis can be successfully adopted to identify priority failure modes on which to act to mitigate risks. The application of this approach to clinical cell therapy manufacturing in regenerative medicine is also discussed.",
keywords = "Cell therapy, FMEA/FMECA, Pareto analysis, Quality risk management, Regenerative medicine",
author = "Fabio Lopez and Bartolo, {Chiara Di} and Tommaso Piazza and Antonino Passannanti and Gerlach, {J{\"o}rg C.} and Bruno Gridelli and Fabio Triolo",
year = "2010",
month = "12",
doi = "10.1111/j.1539-6924.2010.01465.x",
language = "English",
volume = "30",
pages = "1857--1871",
journal = "Risk Analysis",
issn = "0272-4332",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - A Quality Risk Management Model Approach for Cell Therapy Manufacturing

AU - Lopez, Fabio

AU - Bartolo, Chiara Di

AU - Piazza, Tommaso

AU - Passannanti, Antonino

AU - Gerlach, Jörg C.

AU - Gridelli, Bruno

AU - Triolo, Fabio

PY - 2010/12

Y1 - 2010/12

N2 - International regulatory authorities view risk management as an essential production need for the development of innovative, somatic cell-based therapies in regenerative medicine. The available risk management guidelines, however, provide little guidance on specific risk analysis approaches and procedures applicable in clinical cell therapy manufacturing. This raises a number of problems. Cell manufacturing is a poorly automated process, prone to operator-introduced variations, and affected by heterogeneity of the processed organs/tissues and lot-dependent variability of reagent (e.g., collagenase) efficiency. In this study, the principal challenges faced in a cell-based product manufacturing context (i.e., high dependence on human intervention and absence of reference standards for acceptable risk levels) are identified and addressed, and a risk management model approach applicable to manufacturing of cells for clinical use is described for the first time. The use of the heuristic and pseudo-quantitative failure mode and effect analysis/failure mode and critical effect analysis risk analysis technique associated with direct estimation of severity, occurrence, and detection is, in this specific context, as effective as, but more efficient than, the analytic hierarchy process. Moreover, a severity/occurrence matrix and Pareto analysis can be successfully adopted to identify priority failure modes on which to act to mitigate risks. The application of this approach to clinical cell therapy manufacturing in regenerative medicine is also discussed.

AB - International regulatory authorities view risk management as an essential production need for the development of innovative, somatic cell-based therapies in regenerative medicine. The available risk management guidelines, however, provide little guidance on specific risk analysis approaches and procedures applicable in clinical cell therapy manufacturing. This raises a number of problems. Cell manufacturing is a poorly automated process, prone to operator-introduced variations, and affected by heterogeneity of the processed organs/tissues and lot-dependent variability of reagent (e.g., collagenase) efficiency. In this study, the principal challenges faced in a cell-based product manufacturing context (i.e., high dependence on human intervention and absence of reference standards for acceptable risk levels) are identified and addressed, and a risk management model approach applicable to manufacturing of cells for clinical use is described for the first time. The use of the heuristic and pseudo-quantitative failure mode and effect analysis/failure mode and critical effect analysis risk analysis technique associated with direct estimation of severity, occurrence, and detection is, in this specific context, as effective as, but more efficient than, the analytic hierarchy process. Moreover, a severity/occurrence matrix and Pareto analysis can be successfully adopted to identify priority failure modes on which to act to mitigate risks. The application of this approach to clinical cell therapy manufacturing in regenerative medicine is also discussed.

KW - Cell therapy

KW - FMEA/FMECA

KW - Pareto analysis

KW - Quality risk management

KW - Regenerative medicine

UR - http://www.scopus.com/inward/record.url?scp=78649799232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649799232&partnerID=8YFLogxK

U2 - 10.1111/j.1539-6924.2010.01465.x

DO - 10.1111/j.1539-6924.2010.01465.x

M3 - Article

VL - 30

SP - 1857

EP - 1871

JO - Risk Analysis

JF - Risk Analysis

SN - 0272-4332

IS - 12

ER -